Representative Greg Landsman (D-Ohio) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on November 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on October 15th. The trade occurred in the Representative's "SARAH LANDSMAN TRADITIONAL IRA" account.
Representative Greg Landsman also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Pfizer NYSE: PFE on 10/15/2024.
- Sold $1,001 - $15,000 in shares of Cheniere Energy NYSE: LNG on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Phillips 66 NYSE: PSX on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Diamondback Energy NASDAQ: FANG on 10/15/2024.
- Sold $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 10/15/2024.
- Sold $1,001 - $15,000 in shares of Linde NASDAQ: LIN on 10/15/2024.
- Sold $1,001 - $15,000 in shares of CrowdStrike NASDAQ: CRWD on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Exxon Mobil NYSE: XOM on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Amazon.com NASDAQ: AMZN on 10/15/2024.
- Purchased $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 9/10/2024.
Regeneron Pharmaceuticals Stock Down 3.3 %
Shares of REGN stock traded down $25.70 during mid-day trading on Friday, reaching $756.81. 1,374,549 shares of the company's stock traded hands, compared to its average volume of 530,457. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company's 50-day moving average price is $985.21 and its 200-day moving average price is $1,032.97. The company has a market cap of $83.17 billion, a P/E ratio of 18.73, a P/E/G ratio of 3.04 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12 month low of $753.69 and a 12 month high of $1,211.20.
Insider Transactions at Regeneron Pharmaceuticals
In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.48% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on REGN shares. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday. They set an "outperform" rating and a $1,150.00 price objective for the company. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, October 22nd. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada cut their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,099.55.
Read Our Latest Analysis on REGN
Institutional Trading of Regeneron Pharmaceuticals
Large investors have recently made changes to their positions in the business. International Assets Investment Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Capital International Investors grew its stake in Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after purchasing an additional 184,561 shares during the period. Swedbank AB bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $129,257,000. Finally, Worldquant Millennium Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. 83.31% of the stock is currently owned by institutional investors.
About Representative Landsman
Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio's 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Landsman is also a member of the Cincinnati City Council in Ohio. He assumed office on January 2, 2018. His current term ends on January 1, 2024. Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio's 1st Congressional District. He declared candidacy for the 2024 election. Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor's Office of Faith-Based and Community Initiatives.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
See Also
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
